6,963 publications from this institution
The chemical decarbonisation of CaCO 3 was successfully tested in a range of mild temperatures simulating those oscillations occurring within processes, and the kinetic parameters were gained.
Oxidative stress, characterized by an imbalance between increased exposure to free radicals and antioxidant defenses, is a prominent feature of many acute and chronic diseases and even the normal aging process. However, definitive evidence for this association has often been lacking due to recognized shortcomings with methods previously available to assess oxidant stress status in vivo in humans. Several in vitro markers of oxidative stress are available, but most are of limited value in vivo because thay lack sensitivity and/or specificity or require invasive methods. Isoprostanes (IsoPs) are prostaglandin (PG)-like compounds that are produced in vivo independently of cyclooxygenase enzymes, primarily by free radical-induced peroxidation of arachidonic acid. F2-IsoPs are a group of 64 compounds isomeric in structure to cyclooxygenase- derived PGF2α. Other products of the IsoP pathway are also formed in vivo by rearrangement of labile PGH2-like IsoP intermediates including E2- and D2-IsoPs, cyclopentenone-A2- and J2-IsoPs, and highly reactive acyclicketoaldehydes (isoketals). Oxidation of docosahexaenoic acid, an abundant unsaturated fatty acid in the central nervous system, results in the formation of IsoP-like compounds, termed neuroprostanes. Measurement of F2-IsoPs is the most reliable approach to assess oxidative stress status in vivo, providing an important tool to explore the role of oxidative stress in the pathogenesis of human disease. Moreover, F2-IsoPs and other products of the IsoP pathway exert potent biological actions both via receptor-dependent and independent mechanisms and therefore may be pathophysiological mediators of disease. Measurement of F2-IsoPs may provide a uniquely valuable approach to understanding of the clinical pharmacology of antioxidants. Keywords: Isoprostanes, oxidative stress, reactive oxygen species, neuroprostanes, isoketals, eicosanoids, prostaglandins
No abstract is provided for this article.
Chronic obstructive pulmonary disease (COPD), characterized by progressive inflammation in the small airways and lung parenchyma, is mediated by the increased expression of multiple inflammatory genes. The increased expression of these genes is regulated by acetylation of core histones, whereas histone deacetylase 2 (HDAC2) suppresses inflammatory gene expression. In COPD, HDAC2 activity and expression are reduced in peripheral lung and in alveolar macrophages, resulting in amplification of the inflammatory response. Corticosteroid resistance in COPD occurs because corticosteroids use HDAC2 to switch off activated inflammatory genes. The reduction in HDAC2 appears to be secondary to the increased oxidative and nitrative stress in COPD lungs. Antioxidants and inhibitors of nitric oxide synthesis may therefore restore corticosteroid sensitivity in COPD, but this can also be achieved by low concentrations of theophylline and curcumin, which act as HDAC activators.
In this study it is argued that the clinical manifestations of unstable angina pectoris, with at its extreme end impending myocardial infarction, may be due to increased coronary arterial vasomotion superimposed on a pre-existing obstruction in a coronary artery. As nifedipine, a powerful calcium antagonist, has initially proven its efficacy in relieving the symptoms of Prinzmetal's angina, a condition in which severe spasm of the coronary artery is now proven to be the main cause, the drug was given to two groups of patients in whom abnormal vasomotion was suspected and its effects scrutinized. Twelve patients with symptoms of coronary artery disease (CAD) were studied with repeated arteriograms after injection of 0.15 mg nifedipine in the left coronary artery. Two control cine-angiograms were made prior to drug administration and two cinefilms were repeated 30 s and 5 min after administration of nifedipine. The mean diameter of the normal, stenotic and poststenotic segments showed a statistically significant increase after drug administration. Vasodilalion persisted after coronary O 2 saturation, and presumably coronary flow, had returned to normal. In 52 other patients, who were seen in the coronary care unit for impending myocardial infarction and who had been treated with maximal beta-adrenergic blockade, nitrates and bedrest, but who remained symptomatic, nifedipine 60 mg orally for 24 h was added to the treatment. Within 2 h after administration 42 of the 52 became asymptomatic. In the 10 non-responders, all with extensive multi-vessel disease, two sustained a myocardial infarction and eight received urgent coronary artery bypass grafting in an effort to alleviate their symptoms. All had severe 3 vessel disease in contrast to the responders in whom 1 or 2 vessel disease was predominant. These data show that increased coronary artery vasomotion can be influenced by nifedipine. The excellent clinical response to the drug in this group of patients with unstable angina pectoris indicates that nifedipine may become the preferred agent to be used particularly when the cause of the angina pectoris is suspected to be the result of abnormal coronary vasomotor tone.
No abstract is provided for this article.